Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter F Thall

Showing results (111-120 of 190) with videos related to

Pageof 19
Sort By:
Cancer|September 5, 2002
A pilot study of thalidomide in patients with progressive metastatic renal cell carcinomaDanai D Daliani, Christos N Papandreou, Peter F Thall, et al.
Cancers|November 7, 2020
Adverse Event Burden Score-A Versatile Summary Measure for Cancer Clinical TrialsJennifer G Le-Rademacher, Shauna Hillman, Elizabeth Storrick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancerPaul Mathew, Peter F Thall, Donnah Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2002
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostateChristos N Papandreou, Danai D Daliani, Peter F Thall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancerRandall Millikan, Peter F Thall, Sang-Joon Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II studyLance C Pagliaro, Dallas L Williams, Danai Daliani, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2015
Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomasJingya Wang, Denái R Milton, Liru He, et al.
Cancer|January 28, 2003
Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinomaDanai D Daliani, Vasily Assikis, Shi-Ming Tu, et al.
The Journal of Urology|July 19, 2008
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agentsNizar M Tannir, Peter F Thall, Chaan S Ng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancerArlene O Siefker-Radtke, Ashish M Kamat, H Barton Grossman, et al.
Pageof 19

Showing results (111-120 of 190) with videos related to

Sort By:
Pageof 19
Cancer|September 5, 2002
A pilot study of thalidomide in patients with progressive metastatic renal cell carcinomaDanai D Daliani, Christos N Papandreou, Peter F Thall, et al.
Cancers|November 7, 2020
Adverse Event Burden Score-A Versatile Summary Measure for Cancer Clinical TrialsJennifer G Le-Rademacher, Shauna Hillman, Elizabeth Storrick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancerPaul Mathew, Peter F Thall, Donnah Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2002
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostateChristos N Papandreou, Danai D Daliani, Peter F Thall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2003
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancerRandall Millikan, Peter F Thall, Sang-Joon Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II studyLance C Pagliaro, Dallas L Williams, Danai Daliani, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2015
Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomasJingya Wang, Denái R Milton, Liru He, et al.
Cancer|January 28, 2003
Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinomaDanai D Daliani, Vasily Assikis, Shi-Ming Tu, et al.
The Journal of Urology|July 19, 2008
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agentsNizar M Tannir, Peter F Thall, Chaan S Ng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancerArlene O Siefker-Radtke, Ashish M Kamat, H Barton Grossman, et al.
Pageof 19